ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial

Slides:

Advertisements

Similar presentations

Stephen P. McDonald, Graeme R. Russ Kidney International

Advertisements

Volume 67, Pages S1-S7 (June 2005)

MariLia Bahiense Oliveira, Joao Egidio Romao, Roberto Zatz

Frederik Persson, Peter Rossing Kidney International Supplements

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 83, Issue 3, Pages (March 2013)

Management of hypertension in patients with chronic kidney disease

Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,

Metabolic Complications in Elderly Adults With CKD

A Decade After the KDOQI CKD Guidelines

Volume 68, Pages S52-S56 (December 2005)

Volume 61, Issue 2, Pages (February 2002)

Prehypertension and chronic kidney disease: the ox or the plow?

Progression of renal failure and hypertensive nephrosclerosis

John P. Middleton, Patrick H. Pun Kidney International

Burden of chronic kidney disease: North Africa

I. Introduction American Journal of Kidney Diseases

Francesco Paolo Schena Kidney International

Volume 75, Issue 10, Pages (May 2009)

Volume 77, Issue 1, Pages 5-6 (January 2010)

Anemia as a risk factor for chronic kidney disease

Comorbidity and confounding in end-stage renal disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

Volume 63, Issue 2, Pages (February 2003)

Volume 64, Issue 1, Pages (July 2003)

Survival advantage in Asian American end-stage renal disease patients1

Volume 70, Issue 11, Pages (December 2006)

Insulin resistance in African Americans

Manjula Kurella Tamura, Kristine Yaffe Kidney International

The epidemiology of chronic kidney disease

Study of Heart and Renal Protection (SHARP)

Polyunsaturated Fatty Acids and Kidney Disease

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Fructose intake as a risk factor for kidney stone disease

Volume 57, Issue 1, Pages (January 2000)

Volume 69, Issue 3, Pages (February 2006)

Volume 63, Pages S38-S42 (February 2003)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Proteinuria and hypertensive nephrosclerosis in African Americans

Elevated risk of stroke among patients with end-stage renal disease

Nephrology in Latin America, with special emphasis on Brazil

Methods for guideline development

Volume 87, Issue 1, Pages (January 2015)

Volume 76, Issue 8, Pages (October 2009)

Lynda Anne Szczech, Ira L. Lazar Kidney International

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Transforming growth factor beta and progression of renal disease

Volume 80, Issue 3, Pages (August 2011)

Prehypertension: is it relevant for nephrologists?

Homocysteine, renal function, and risk of cardiovascular disease

Douglas G Matsell, Colin T White Kidney International

Stephen P. McDonald, Graeme R. Russ Kidney International

Volume 64, Issue 2, Pages (August 2003)

Long-term survival in renal transplant recipients with graft function

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Unraveling the racial disparities associated with kidney disease1

Peritoneal dialysis in Mexico

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Volume 60, Issue 1, Pages (July 2001)

The Danish Renal Biopsy Register

Volume 80, Issue 10, Pages (November 2011)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Michael R. Lattanzio, Matthew R. Weir Kidney International

Charles A. Herzog Kidney International

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Kidney and hypertension

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Presentation transcript:

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial Janice G. Douglas, Lawrence Agodoa Kidney International Volume 63, Pages S74-S76 (February 2003) DOI: 10.1046/j.1523-1755.63.s83.15.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Relative risk reduction for patients randomized to ramipril (N = 436) as compared to those assigned to amlodipine (N = 217). Abbreviations are: GFR, glomerular filtration rate; ESRD, end-stage renal disease. Reprinted with permission. Advances in Cardiology. Eugene Raunwald (ed). McGraw-Hill, 2003. Kidney International 2003 63, S74-S76DOI: (10.1046/j.1523-1755.63.s83.15.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Change in glomerular filtration rate in the ramipril () and amlodipine (▪) groups from baseline at six and 36 months. Reprinted with permission. Advances in Cardiology. Eugene Raunwald (ed). McGraw-Hill, 2003. Kidney International 2003 63, S74-S76DOI: (10.1046/j.1523-1755.63.s83.15.x) Copyright © 2003 International Society of Nephrology Terms and Conditions